Immuneering Q3 net loss $8.5M ($0.47/sh); cash $159.6M; IND for IMM-1-104 in Q1 2022

Immuneering Corp

2021-Q3 EPS reported -$2.41 revenue$1,890,370

Net loss attributable to common stockholders $8.5M vs $4.4M in Q3 2020; diluted EPS $(0.47).
Cash and marketable securities $159.6M as of Sep 30, 2021, up from $37.1M at Dec 31, 2020.
Completed upsized IPO of 8.625M shares at $15.00 each, gross proceeds $129.4M.
IND filing for dual-MEK inhibitor IMM-1-104 expected Q1 2022; Phase 1 trial in 1H 2022.
R&D expenses $6.2M (up from $4.1M); G&A $2.6M (up from $0.7M) due to IPO prep and headcount.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.